Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
ARTBIO Inc.
Conjupro Biotherapeutics, Inc.
IDEAYA Biosciences
Eli Lilly and Company
National Cancer Institute (NCI)
GlaxoSmithKline
Eli Lilly and Company
K36 Therapeutics, Inc.
Orano Med LLC
Eli Lilly and Company
Mayo Clinic
Alterome Therapeutics, Inc.
ViroMissile, Inc.
Pfizer
Tizona Therapeutics, Inc
Clasp Therapeutics, Inc.
Angiex, Inc.
Werewolf Therapeutics, Inc.
MacroGenics
Adaptimmune
Astellas Pharma Inc
HiberCell, Inc.
Memorial Sloan Kettering Cancer Center
OncoNano Medicine, Inc.
City of Hope Medical Center
MOMA Therapeutics
Sairopa B.V.
AccSalus Biosciences, Inc.
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Incyte Corporation
M.D. Anderson Cancer Center
Nurix Therapeutics, Inc.
Kazia Therapeutics Limited
Pfizer
Incyte Corporation
Trishula Therapeutics, Inc.
Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
University of California, San Francisco
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
NextPoint Therapeutics, Inc.
Exelixis
Amgen
M.D. Anderson Cancer Center
Zhejiang University
Orion Biotechnology Polska Sp. z o.o.
National Cancer Institute (NCI)